[Image courtesy of Wikimedia Commons]
Pfizer (NYSE:PFE) and BioNTech (Nasdaq:BNTX) have announced that their omicron BA.4/BA.5-adapted bivalent booster fared well against novel omicron variants in neutralizing antibody detection tests.The company published the results from the bivalent booster tests against the BA.4.6, BA.2.75.2, BQ.1.1 and XBB.1 subvariants on the preprint server BioRxiv.
One month after administering a fourth vaccine dose, the geometric means of neutralization titers from the bivalent BA.4/5 vaccine was generally superior to that of the monovalent BNT162b2 booster. Overall, the Omicron BA.4/BA.5-adapted bivalent COVID-19 vaccine was associated with a 3.2- to 4.8-fold increase in neutralizing antibody titers relative to the original monovalent Pfizer-BioNTech vaccine. For the BA.4.6, BA.2.75.2, BQ.1.1 and XBB.1 omicron variants, antibody titers were up between 4.8- to 11.1-fold from pre…